



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/519,044	09/02/2005	Robert Norman Barker	0380-P03549US0	6955
110	7590	07/06/2009	EXAMINER	
DANN, DORFMAN, HERRELL & SKILLMAN			JUEDES, AMY E	
1601 MARKET STREET			ART UNIT	PAPER NUMBER
SUITE 2400			1644	
PHILADELPHIA, PA 19103-2307			MAIL DATE	DELIVERY MODE
			07/06/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/519,044	<b>Applicant(s)</b> BARKER ET AL.
	<b>Examiner</b> AMY E. JUEDES	<b>Art Unit</b> 1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 16 April 2009.
- 2a) This action is FINAL.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 3-13 and 15-50 is/are pending in the application.
- 4a) Of the above claim(s) 3-5,8-13,15-40,44-46,48 and 50 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 6,7,41-43,47 and 49 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO/SB/08)  
 Paper No(s)/Mail Date \_\_\_\_\_
- 4) Interview Summary (PTO-413)  
 Paper No(s)/Mail Date \_\_\_\_\_
- 5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_

**DETAILED ACTION**

1. Applicant's election with traverse of atopic/allergic disease as the species of disease to be treated, in the reply filed on 4/16/09, is acknowledged.

Applicant's traversal is on the grounds that the '008 patent teaches administering LMP proteins for therapy of EBV infection, while the instant claims are specifically directed to the prophylaxis or treatment of a condition mediated by an immune response against a target antigen, such as an autoimmune disease, allergy, etc. Applicant further asserts an EBV protein can not be considered a target antigen, since claim 47 requires that the sequences of the toleragenic peptide be different from those corresponding to the target antigen. The '008 patent teaches administering fusion proteins comprising peptide epitopes from multiple different EBV latent viral proteins, including LMP1 (see column 15 and 22, in particular). Thus, the LMP1 peptide (i.e. the "toleragenic peptide" would have a different sequence than that of the other latent viral peptide to which it is fused. Additionally, The '008 patent teaches that immune response to EBV proteins correlate with various diseases (i.e. said diseases are mediated by an immune response against said proteins, see column 9 and 17 of the '008 patent, in particular). The '008 patent teaches that the method comprising administering the EBV proteins, including LMP, is suitable for treatment of said diseases. Thus, the EBV viral proteins can be considered "target antigens".

The requirement is still deemed proper and is therefore made FINAL.

Claims 3-5, 8-13, 15-40, and 44-46 stand withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention. Claims 48 and 50 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to non-elected species.

Claims 6-7, 41-43, 47, and 49 read on the elected invention and are being acted upon.

2. In view of Applicant's amendment to the claims, the previous grounds of rejection are withdrawn.

3. The following are new grounds of rejection.
4. The following is a quotation of the second paragraph of 35 U.S.C. 112:  
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.  
Claims 6-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
  - A) Claim 6 recites the limitation "said subject" in line 3. There is insufficient antecedent basis for this limitation in the claim, or in independent claim 47.
  - B) Claim 7 is indefinite in the recitation of the peptides sequences "P2, P4, P7...". The use of "P2, P4, etc" as the only means of identifying the peptides renders the claim indefinite because "P2" is merely a laboratory designation. Since different laboratories may use the same laboratory designation to define completely distinct biological materials, said laboratory designation does not clearly define the peptides. The rejection can be overcome by amending the claims to recite specific SEQ ID NOs.
5. The following is a quotation of the first paragraph of 35 U.S.C. 112:  
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.  
Claims 6-7, 41-43, and 47 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for:  
a method of treatment/prophylaxis of autoimmune disease, atopic/allergic disease, or graft rejection comprising administering a target antigen and a toleragenic peptide sequence from EBV encoded LMP1 or LMP2 protein, thereby inhibiting the immune response to the target antigen,  
does not reasonably provide enablement for:

a method of prophylaxis/treatment of a disease or condition mediated by an immune response against a target antigen comprising administering a target antigen and a toleragenic peptide sequence from EBV encoded LMP1 or LMP2 protein, thereby inducing immune tolerance to the target antigen.

The specification disclosure is insufficient to enable one skilled in the art to practice the invention as claimed without an undue amount of experimentation. Undue experimentation must be considered in light of factors including: the breadth of the claims, the nature of the invention, the state of the prior art, the level of one of ordinary skill in the art, the level of predictability of the art, the amount of direction provided by the inventor, the existence of working examples, and the quantity of experimentation needed to make or use the invention, *in re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988).

"The amount of guidance or direction needed to enable the invention is inversely related to the amount of knowledge in the state of the art as well as the predictability in the art." *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). The "amount of guidance or direction" refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictable the art is, the less information needs to be explicitly stated in the specification. In contrast, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail as to how to make and use the invention in order to be enabling (MPEP 2164.03)" The MPEP further states that physiological activity can be considered inherently unpredictable.

The specification provides insufficient guidance to enable claims drawn to the method as broadly claimed. The instant claims are drawn to a method of prophylaxis or treatment of a disease or condition mediated by an immune response against a target antigen, wherein the method results in the induction of tolerance to said target antigen. This might encompass treating a broad range of diseases or conditions mediated by completely different pathological mechanisms. For example, the claims might encompass treating HIV, which is involves the destruction of HIV infected CD4 T cells

Art Unit: 1644

(i.e. an "immune response against a target antigen"). However, as taught by Burgers et al., one of the primary goals of treating HIV involves inducing a sufficient immune response against the virus, and ability to treat HIV by inducing tolerance to target HIV antigens would thus be extremely unpredictable. Furthermore, the instant claims might encompass treating Alzheimer's disease, which involves (i.e. is mediated by) an immune response against target CNS antigens (see Mor et al., 2005). However, Mor et al. also teach that under certain circumstances the immune response against said target antigens might actually be protective and be involved in the clearance of amyloid deposits. Thus, inhibiting an immune response to Alzheimer's target antigens by inducing tolerance with the claimed method would be extremely unpredictable, since it might actually inhibit a protective immune response involved in clearing amyloid deposits.

Furthermore, the instant claims specify that the method results in the induction of "immune tolerance" to the target antigen. While, it might be possible to inhibit an immune response to a target antigen, induction of "tolerance" encompasses completely preventing any response to the antigen. Thus, given the breadth of the claims and the unpredictability of the art, the instant specification must provide a sufficient enabling disclosure commensurate in scope with the instant claims. The instant specification demonstrates that various peptides of EBV1 encoded LMP1 and LMP2 can suppress the immune response to a target antigen *in vitro*, including to allergen or alloantigen target antigens. Given, the ability of the LMP1/LMP2 peptides to suppress the immune response to a target antigen, it would be reasonable to administer the LMP peptide and target antigens *in vivo* to suppress the immune response to the target antigen for treatment of autoimmune disease, allergy, or graft rejection. However, the instant specification does not provide any guidance regarding treating the diseases as broadly claimed (for example, Alzheimer's or HIV infection, which operate by completely different pathological mechanisms than autoimmune disease, allergy, or graft rejection). Furthermore, the instant specification demonstrates that the LMP peptides inhibit the immune response to the target antigens, but do not completely prevent said immune response (i.e. do not induce a complete "tolerance" as is encompassed by the instant

claims. Accordingly, the method as broadly claimed must be considered highly unpredictable. Given said unpredictability, the method of the instant claims must be considered to require undue experimentation.

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-2, 6-7, 41-43, 47, and 49 are rejected under 35 102(e) as being anticipated by U.S. Patent 6,642,008 (of record), as evidenced by Dukers et. al., 2000 (of record) and Wakiguchi et al., 2002.

The '008 patent teaches administering EBV encoded LMP1 protein to a subject seropositive for EBV (see column 7-8 and 15, in particular). As evidenced by Dukers et al., said EBV encoded LMP1 protein comprises the sequence of peptide P4 of the instant application (see page 664 and Table I in particular, residues 16-35). The '008 patent also teaches that the LMP1 protein can be in the form of a fusion protein with other EBV proteins (i.e. a "target antigen", see column 15 in particular). Furthermore, the '008 patent teaches that immune response to EBV viral antigens correlates with diseases such as atopic disease (i.e. said diseases are mediated by an immune response against said viral "target antigens", see column 5 and 17 of the '008 patent, in particular). Additionally, as evidenced by Wakiguchi, 2002, mosquito allergy is associated with EBV (i.e. EBV is an antigen which provokes an allergic immune response). Thus, the EBV target antigens administered in the method of the '008 patent are inherently antigens which "provoke" an allergic immune response.

Thus, the reference clearly anticipates the invention.

7. No claim is allowed.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy E. Juedes, whose telephone number is 571-272-4471. The examiner can normally be reached on 7am to 3:30pm, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Amy E. Juedes  
Patent Examiner  
Technology Center 1600  
/Amy E. Juedes/  
Examiner, Art Unit 1644